Similar articles for PMID: 20498238

Year	Number of Results
2005	1
2006	2
2007	1
2008	7
2009	12
2010	35
2011	37
2012	51
2013	61
2014	50
2015	33
2016	14
2017	11
2018	16
2019	13
2020	6
2021	0

1

Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis.

Rhee EP, Laliberte KA, Niles JL. Rhee EP, et al. Clin J Am Soc Nephrol. 2010 Aug;5(8):1394-400. doi: 10.2215/CJN.08821209. Epub 2010 May 24. Clin J Am Soc Nephrol. 2010. PMID: 20498238 Free PMC article.

2

Rituximab treatment for vasculitis.

Jayne D. Jayne D. Clin J Am Soc Nephrol. 2010 Aug;5(8):1359-62. doi: 10.2215/CJN.05500610. Epub 2010 Jul 29. Clin J Am Soc Nephrol. 2010. PMID: 20671223 Free article. No abstract available.

3

Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.

Smith RM, Jones RB, Guerry MJ, Laurino S, Catapano F, Chaudhry A, Smith KG, Jayne DR. Smith RM, et al. Arthritis Rheum. 2012 Nov;64(11):3760-9. doi: 10.1002/art.34583. Arthritis Rheum. 2012. PMID: 22729997 Free article.

4

[The role of rituximab in the treatment of ANCA-associated systemic vasculitis].

Roccatello D, Vangelista A, Pani A. Roccatello D, et al. G Ital Nefrol. 2011 Sep-Oct;28(5):474-88. G Ital Nefrol. 2011. PMID: 22028261 Review. Italian.

5

Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis.

Pendergraft WF 3rd, Cortazar FB, Wenger J, Murphy AP, Rhee EP, Laliberte KA, Niles JL. Pendergraft WF 3rd, et al. Clin J Am Soc Nephrol. 2014 Apr;9(4):736-44. doi: 10.2215/CJN.07340713. Epub 2014 Mar 13. Clin J Am Soc Nephrol. 2014. PMID: 24626432 Free PMC article.

6

Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre.

Pullerits R, Ljevak M, Vikgren J, Bokarewa M. Pullerits R, et al. Scand J Immunol. 2012 Oct;76(4):411-20. doi: 10.1111/j.1365-3083.2012.02747.x. Scand J Immunol. 2012. PMID: 22823472 Free article.

7

B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.

Gómez-Puerta JA, Quintana LF, Stone JH, Ramos-Casals M, Bosch X. Gómez-Puerta JA, et al. Autoimmun Rev. 2012 Jul;11(9):646-52. doi: 10.1016/j.autrev.2011.11.007. Epub 2011 Nov 21. Autoimmun Rev. 2012. PMID: 22146313 Review.

8

Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.

Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D. Stasi R, et al. Rheumatology (Oxford). 2006 Nov;45(11):1432-6. doi: 10.1093/rheumatology/kel098. Epub 2006 Apr 21. Rheumatology (Oxford). 2006. PMID: 16632482 Clinical Trial.

9

[Rituximab for the treatment of ANCA associated vasculitis: the future today?].

Alba MA, Flores-Suárez LF. Alba MA, et al. Reumatol Clin. 2011 Dec;7 Suppl 3:S41-6. doi: 10.1016/j.reuma.2011.10.006. Epub 2011 Nov 23. Reumatol Clin. 2011. PMID: 22115869 Free article. Review. Spanish.

10

ANCA vasculitis: time for a change in treatment paradigm? Not yet.

Ntatsaki E, Mooney J, Watts RA. Ntatsaki E, et al. Rheumatology (Oxford). 2011 Jun;50(6):1019-24. doi: 10.1093/rheumatology/ker002. Epub 2011 Feb 3. Rheumatology (Oxford). 2011. PMID: 21292735 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed